EUVIMEDEUVIMED entdecken
Klinische Studie (Phase III)Randomisierte kontrollierte StudieOpen Access

Zanubrutinib Versus Ibrutinib in Relapsed/Refractory Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma: Interim Analysis of a Randomized Phase III Trial

Peter Hillmen iD, Barbara Eichhorst, Jennifer R Brown iD, Nicole Lamanna iD, Susan M O'Brien, Constantine S Tam iD, Lugui Qiu, Maciej Kazmierczak, Keshu Zhou, Martin Šimkovič iD, Jiří Mayer, Amanda Gillespie-Twardy und 16 weitere

Journal of Clinical Oncology · 10.02.2023 · 41 (5) · 1035-1045

DOI: 10.1200/jco.22.00510 ↗

Kurz gefasst

Klinische Studie (Phase III) in der Zeitschrift Journal of Clinical Oncology, erschienen am 10.02.2023. Verfasst von Peter Hillmen und 27 weiteren Autor:innen. Beteiligte Einrichtung: St James's University Hospital, Leeds, United Kingdom. Hauptthemen laut MEDLINE: Leukemia, Lymphocytic, Chronic, B-Cell, Atrial Fibrillation, Lymphoma, B-Cell. Die Arbeit wurde bisher 94-mal zitiert (Crossref) und nennt 21 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE Zanubrutinib is a potent, irreversible next-generation Bruton tyrosine kinase (BTK) inhibitor designed to maximize BTK occupancy and minimize off-target kinase inhibition. We hypothesized that complete/sustained BTK occupancy may improve efficacy outcomes and increased BTK specificity may minimize off-target inhibition-related toxicities. PATIENTS AND METHODS ALPINE (ClinicalTrials.gov identifier: NCT03734016 ) is a global, randomized, open-label phase III study of zanubrutinib versus ibrutinib in patients with relapsed/refractory chronic lymphocytic leukemia. The primary end point was investigator-assessed overall response rate (ORR). The preplanned interim analysis was scheduled approximately 12 months after the first 415 patients were enrolled. RESULTS Between November 1, 2018, and December 14, 2020, 652 patients were enrolled. We present the interim analysis of the first 415 enrolled patients randomly assigned to receive zanubrutinib (n = 207) or ibrutinib (n = 208). At 15 months of median follow-up, ORR (partial or complete response) was significantly higher with zanubrutinib (78.3%; 95% CI, 72.0 to 83.7) versus ibrutinib (62.5%; 95% CI, 55.5 to 69.1; two-sided P < .001). ORR was higher with zanubrutinib versus ibrutinib in subgroups with del(17p)/ TP53 mutations (80.5% v 50.0%) and del(11q) (83.6% v 69.1%); 12-month progression-free survival in all patients was higher with zanubrutinib (94.9%) versus ibrutinib (84.0%; hazard ratio, 0.40; 95% CI, 0.23 to 0.69). Atrial fibrillation rate was significantly lower with zanubrutinib versus ibrutinib (2.5% v 10.1%; two-sided P = .001). Rates of cardiac events, major hemorrhages, and adverse events leading to treatment discontinuation/death were lower with zanubrutinib. CONCLUSION Zanubrutinib had a significantly higher ORR, lower atrial fibrillation rate, and improved progression-free survival and overall cardiac safety profile versus ibrutinib. These data support improved efficacy/safety outcomes with selective BTK inhibition.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Leukemia, Lymphocytic, Chronic, B-CellAtrial FibrillationLymphoma, B-CellHumansAdenineProtein Kinase InhibitorsPiperidinesPyrazolesPyrimidines

Substanzen

AdenineProtein Kinase InhibitorsibrutinibPiperidineszanubrutinibPyrazolesPyrimidines

Autor:innen und Institutionen

  • St James's University Hospital, Leeds, United Kingdom.
  • Department I of Internal Medicine, Center for Integrated Oncology Aachen, University of Cologne, Bonn, Cologne, Düsseldorf, Germany.
  • Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA.
  • Herbert Irving Comprehensive Cancer Center, Columbia University, New York, NY.
  • Chao Family Comprehensive Cancer Center, University of California, Irvine, CA.
  • Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.

ORCID-Profile: Peter Hillmen, Jennifer R Brown, Nicole Lamanna, Constantine S Tam, Martin Šimkovič, Alessandra Ferrajoli, Tadeusz Robak, Meng Ji

Zitieren

APA

Hillmen, P., Eichhorst, B., Brown, J. R., Lamanna, N., O'Brien, S. M., Tam, C. S., Qiu, L., Kazmierczak, M., Zhou, K., Šimkovič, M., Mayer, J., Gillespie-Twardy, A., Shadman, M., Ferrajoli, A., Ganly, P. S., Weinkove, R., Grosicki, S., Mital, A., Robak, T., …, & Jurczak, W. (2023). Zanubrutinib Versus Ibrutinib in Relapsed/Refractory Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma: Interim Analysis of a Randomized Phase III Trial. Journal of Clinical Oncology, 41(5), 1035-1045. https://doi.org/10.1200/jco.22.00510

Vancouver

Hillmen P, Eichhorst B, Brown JR, Lamanna N, O'Brien SM, Tam CS, et al. Zanubrutinib Versus Ibrutinib in Relapsed/Refractory Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma: Interim Analysis of a Randomized Phase III Trial. Journal of Clinical Oncology. 2023;41(5):1035-1045. doi:10.1200/jco.22.00510

BibTeX
@article{Hillmen2023,
  author = {Hillmen, Peter and Eichhorst, Barbara and Brown, Jennifer R and Lamanna, Nicole and O'Brien, Susan M and Tam, Constantine S and Qiu, Lugui and Kazmierczak, Maciej and Zhou, Keshu and Šimkovič, Martin and Mayer, Jiří and Gillespie-Twardy, Amanda and Shadman, Mazyar and Ferrajoli, Alessandra and Ganly, Peter S and Weinkove, Robert and Grosicki, Sebastian and Mital, Andrzej and Robak, Tadeusz and Österborg, Anders and Yimer, Habte A and Salmi, Tommi and Ji, Meng and Yecies, Jessica and Idoine, Adam and Wu, Kenneth and Huang, Jane and Jurczak, Wojciech},
  title = {Zanubrutinib Versus Ibrutinib in Relapsed/Refractory Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma: Interim Analysis of a Randomized Phase III Trial},
  journal = {Journal of Clinical Oncology},
  year = {2023},
  volume = {41},
  number = {5},
  pages = {1035--1045},
  doi = {10.1200/jco.22.00510}
}
Kostenlos starten →